Terms: = Gastric cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
438 results:
1. New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model.
Yu D; Yang J; Wang B; Li Z; Wang K; Li J; Zhu C
Cancer Immunol Immunother; 2024 May; 73(6):112. PubMed ID: 38693422
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract] [Full Text] [Related]
3. Creatinine-to-cystatin C ratio and body composition predict response to pd-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract] [Full Text] [Related]
4. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
5. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract] [Full Text] [Related]
6. Combination of IFN-gamma with STING agonist and pd-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer.
Hosseinzadeh S; Imani M; Pourfarzi F; Jafari N; AbedianKenari S; Safarzadeh E
Med Oncol; 2024 Apr; 41(5):110. PubMed ID: 38592576
[TBL] [Abstract] [Full Text] [Related]
7. First-line camrelizumab (a pd-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
[TBL] [Abstract] [Full Text] [Related]
8. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.
Peng H; Wu X; Zhang C; Liang Y; Cheng S; Zhang H; Shen L; Chen Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):153. PubMed ID: 38519621
[TBL] [Abstract] [Full Text] [Related]
9.
Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
[TBL] [Abstract] [Full Text] [Related]
10. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract] [Full Text] [Related]
11. Case report: A case of advanced gastric cancer with multiple skin metastases, with significant relief from immunotherapy.
Hao W; Chang R; Liu J; Wang Y; Ren M; Xin K; Liu B; Xie J; Yang Y
Front Immunol; 2024; 15():1356350. PubMed ID: 38500887
[TBL] [Abstract] [Full Text] [Related]
12. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract] [Full Text] [Related]
13. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.
Li F; Feng Q; Tao R
Medicine (Baltimore); 2024 Mar; 103(10):e37314. PubMed ID: 38457593
[TBL] [Abstract] [Full Text] [Related]
14. How to use anti-pd-1 therapy in gastric cancer: the approach in the United States.
Ilson DH
Chin Clin Oncol; 2024 Feb; 13(1):7. PubMed ID: 38453657
[TBL] [Abstract] [Full Text] [Related]
15. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
[TBL] [Abstract] [Full Text] [Related]
16. Who Should Receive Immunotherapy for Advanced Gastroesophageal cancer?
Khateeb S; Cavalcante L; Alnairat N; Singh M; Sahin IH; Saeed A; Saeed A
Curr Treat Options Oncol; 2024 Apr; 25(4):496-509. PubMed ID: 38372852
[TBL] [Abstract] [Full Text] [Related]
17. Identification of the exosomal PD-L1 inhibitor to promote the pd-1 targeting therapy of gastric cancer.
Sun JG; Gao Y; Gao YS; Dai XJ; Chen P
Eur J Med Chem; 2024 Mar; 268():116182. PubMed ID: 38367489
[TBL] [Abstract] [Full Text] [Related]
18. Apatinib Plus Toripalimab (Anti-pd1 Therapy) as Second-Line Therapy in Patients With Advanced gastric or Esophagogastric Junction cancer: Results From a Randomized, Open-Label Phase II Study.
Wei Q; Xu X; Li J; Wang C; Chen W; Xie Y; Luo C; Chen L; Chu J; Wu W; Han Z; Yang Y; Hu Z; Xu Q; Ying J
Oncologist; 2024 Apr; 29(4):364-e578. PubMed ID: 38366886
[TBL] [Abstract] [Full Text] [Related]
19. Combination treatment with anti-HER2 therapeutic antibody RC48, pd-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.
Liu Z; Wang F; Zhang Y; Lu J; Yang Y
Front Immunol; 2024; 15():1321946. PubMed ID: 38361930
[TBL] [Abstract] [Full Text] [Related]
20. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of pd-1 inhibitor in gastric cancer.
Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
[TBL] [Abstract] [Full Text] [Related]
[Next]
